Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -169.64% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-169.64%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.53%
median of 486 covered companies
CURRENT VS SECTOR MEDIAN
-340.29%
vs the sector median at left
Lakewood-Amedex Biotherapeutics, Inc.
Market Cap
$1.47M
Return on Equity (ROE)
-169.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.47M
Return on Equity (ROE)
-32.05%
TTM Avg
-197.10%
3Y Avg
-44.98%
5Y Avg
-69.38%
Market Cap
$1.48M
Return on Equity (ROE)
-450.54%
TTM Avg
292.29%
3Y Avg
55.45%
5Y Avg
24.80%
Market Cap
$1.44M
Return on Equity (ROE)
-80.57%
TTM Avg
-96.07%
3Y Avg
-115.92%
5Y Avg
51.19%
Market Cap
$1.43M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
Market Cap
$1.32M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
Market Cap
$1.20M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
Market Cap
$1.20M
Return on Equity (ROE)
N/A
TTM Avg
206.72%
3Y Avg
141.32%
5Y Avg
115.74%
Market Cap
$1.12M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics, Inc. (LABT) | $1.47M | -169.64% | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.47M | -32.05% | -197.10% | -44.98% | -69.38% |
| Curis, Inc. (CRIS)vs › | $1.48M | -450.54% | 292.29% | 55.45% | 24.80% |
| PMGC Holdings Inc. (ELAB)vs › | $1.44M | -80.57% | -96.07% | -115.92% | 51.19% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.43M | -253.57% | 334.28% | 134.39% | 95.16% |
| Genprex, Inc. (GNPX)vs › | $1.32M | -111.51% | -753.43% | -507.39% | -356.28% |
| IM Cannabis Corp. (IMCC)vs › | $1.20M | N/A | 558.67% | 54.46% | -8.27% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | N/A | 206.72% | 141.32% | 115.74% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.12M | -11.85% | -6.20% | 47.36% | 47.36% |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | -57.87% | -222.45% | -164.72% | -135.78% |
ROE
-169.6%
ROA
-148.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -169.64% |
